Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,797.50
82.40 (4.80%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹2.40K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
22.3
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹416+332.1%
52W High₹1,800.8-0.2%
Current Price
₹1,797.50
Circuit Limits (5%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,707.63
Upper Circuit₹1,887.38
Reference Price
₹1,797.50
Investment Checklist
Double Bottom on 1W (BREAKOUT CONFIRMED) — target ₹552.2
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹552.2
Composite score 62.5 (STRONG_BUY) with 87.7% confidence
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
3-day momentum: +11.6% — strong upward pressure
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
88%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1414.42
EMA50
1185.68
EMA200
834.8
Price Action
UPTREND
BULLISH
Higher Highs8
Higher Lows8
Lower Highs1
Lower Lows1
Support & Resistance Levels
Resistance (Above)
No recent resistance detected
Support (Below)
₹1088.80
₹1027.95
₹944.75
₹904.72
₹880.05
Volume Analysis
TrendINCREASING
Change+197.00%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹1779.53
3% Risk₹1743.58
5% Risk₹1707.63
7% Risk (Custom)
₹1671.67Technical Levels
1x ATR (Volatility)₹1720.52
2x ATR (Swing)₹1643.54
3x ATR (Trend)₹1566.56
Immediate Support₹1088.80
Moving Averages
EMA 9 (Short-term)₹1602.12
EMA 20 (Medium-term)₹1414.42
EMA 50 (Trend)₹1185.68
EMA 200 (Long-term)₹834.80
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹194.4 Cr | ₹131.9 Cr | ₹192.8 Cr | ₹180.3 Cr |
| Net Profit | ₹21 Cr | ₹9.6 Cr | ₹20.1 Cr | ₹25.6 Cr |
| EPS | — | ₹7.18 | ₹15.06 | ₹19.14 |
| Operating Profit | ₹35.8 Cr | ₹18.8 Cr | ₹32.7 Cr | ₹40 Cr |
ROE
8.08%
ROCE
12.78%
Debt/Equity
0.00
Current Ratio
3.31
OPM
22.21%
NPM
14.19%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 13 Sept 2024 | Annual General Meeting | AGM |
| 17 Aug 2023 | Annual General Meeting | AGM |
| 11 Aug 2022 | Annual General Meeting | AGM |
| 09 Sept 2021 | Annual General Meeting | AGM |
| 24 Nov 2020 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for VENUSREM
View AllNEWS
positive
Business Standard - Markets 17d ago
Venus Remedies consolidated net profit rises 126.19% in the March 2026 quarter
Sales rise 33.05% to Rs 259.40 crore
VENUSREMHealthcare
NEWS
positive
Business Standard - Markets 17d ago
Venus Remedies standalone net profit rises 193.78% in the March 2026 quarter
Sales rise 31.65% to Rs 259.01 crore
VENUSREMHealthcare
positive
ET Markets - Industry 21d ago
Venus Remedies gets Saudi FDA approval for speciality oncology therapy
Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.
GLOBALSPECIALITYVENUSREMVIDHIINGChemicalsConsumer Services